Medication Use in the Neonatal Intensive Care Unit
12 July 2013
14 October 2013
17 December 2013 (eFirst)
Objective The aim of the article is to provide an update on medication use in infants admitted to the neonatal intensive care unit (NICU) in the United States and examine how use has changed over time.
Study Design We performed a retrospective review (2005–2010) of a large prospectively collected administrative database.
Result Medications most commonly administered during the study period were ampicillin, gentamicin, caffeine citrate, vancomycin, beractant, furosemide, fentanyl, dopamine, midazolam, and calfactant (56–681 exposures per 1,000 infants). Those with the greatest relative increase in use included azithromycin, sildenafil, and milrinone. Medications with the greatest relative decrease in use included theophylline, metoclopramide, and doxapram.
Conclusion Medication use in the NICU has changed substantially over time, and only 35% of the most commonly prescribed medications are Food and Drug Administration –approved in infants.
- 1 Barr J, Brenner-Zada G, Heiman E , et al. Unlicensed and off-label medication use in a neonatal intensive care unit: a prospective study. Am J Perinatol 2002; 19 (2) 67-72
- 2 Bavdekar SB, Gogtay NJ. Unlicensed and off-label drug use in children. J Postgrad Med 2005; 51 (4) 249-252
- 3 Pandolfini C, Bonati M. A literature review on off-label drug use in children. Eur J Pediatr 2005; 164 (9) 552-558
- 4 Cuzzolin L, Atzei A, Fanos V. Off-label and unlicensed prescribing for newborns and children in different settings: a review of the literature and a consideration about drug safety. Expert Opin Drug Saf 2006; 5 (5) 703-718
- 5 Conroy S, McIntyre J. The use of unlicensed and off-label medicines in the neonate. Semin Fetal Neonatal Med 2005; 10 (2) 115-122
- 6 Clark RH, Bloom BT, Spitzer AR, Gerstmann DR. Reported medication use in the neonatal intensive care unit: data from a large national data set. Pediatrics 2006; 117 (6) 1979-1987
- 7 Horen B, Montastruc J-L, Lapeyre-Mestre M. Adverse drug reactions and off-label drug use in paediatric outpatients. Br J Clin Pharmacol 2002; 54 (6) 665-670
- 8 Moore TJ, Weiss SR, Kaplan S, Blaisdell CJ. Reported adverse drug events in infants and children under 2 years of age. Pediatrics 2002; 110 (5) e53
- 9 Kaufman D, Boyle R, Hazen KC, Patrie JT, Robinson M, Grossman LB. Twice weekly fluconazole prophylaxis for prevention of invasive Candida infection in high-risk infants of <1000 grams birth weight. J Pediatr 2005; 147 (2) 172-179
- 10 Manzoni P, Stolfi I, Pugni L , et al; Italian Task Force for the Study and Prevention of Neonatal Fungal Infections; Italian Society of Neonatology. A multicenter, randomized trial of prophylactic fluconazole in preterm neonates. N Engl J Med 2007; 356 (24) 2483-2495
- 11 Kaufman DA, Manzoni P. Strategies to prevent invasive candidal infection in extremely preterm infants. Clin Perinatol 2010; 37 (3) 611-628
- 12 Wade KC, Wu D, Kaufman DA , et al; National Institute of Child Health and Development Pediatric Pharmacology Research Unit Network. Population pharmacokinetics of fluconazole in young infants. Antimicrob Agents Chemother 2008; 52 (11) 4043-4049
- 13 Hibbs AM, Lorch SA. Metoclopramide for the treatment of gastroesophageal reflux disease in infants: a systematic review. Pediatrics 2006; 118 (2) 746-752
- 14 U.S. Food and Drug Administration. Reglan (metoclopramide) tablets, ODT (orally disintegrating tablets), and injection. Available at: http://www.fda.gov/Safety/MedWatch/SafetyInformation/ucm170934.htm . Accessed July 6, 2012
- 15 Spitzer AR, Ellsbury DL, Handler D, Clark RH. The Pediatrix BabySteps Data Warehouse and the Pediatrix QualitySteps improvement project system—tools for “meaningful use” in continuous quality improvement. Clin Perinatol 2010; 37 (1) 49-70
- 16 Clark RH, Spitzer AR. Patience is a virtue in the management of gastroesophageal reflux. J Pediatr 2009; 155 (4) 464-465
- 17 Guillet R, Stoll BJ, Cotten CM , et al; National Institute of Child Health and Human Development Neonatal Research Network. Association of H2-blocker therapy and higher incidence of necrotizing enterocolitis in very low birth weight infants. Pediatrics 2006; 117 (2) e137-e142
- 18 Benjamin Jr DK, Stoll BJ, Fanaroff AA , et al; National Institute of Child Health and Human Development Neonatal Research Network. Neonatal candidiasis among extremely low birth weight infants: risk factors, mortality rates, and neurodevelopmental outcomes at 18 to 22 months. Pediatrics 2006; 117 (1) 84-92
- 19 Van Overmeire B, Smets K, Lecoutere D , et al. A comparison of ibuprofen and indomethacin for closure of patent ductus arteriosus. N Engl J Med 2000; 343 (10) 674-681
- 20 Greenough A. Long term respiratory outcomes of very premature birth (<32 weeks). Semin Fetal Neonatal Med 2012; 17 (2) 73-76
- 21 Barst RJ, Ivy DD, Gaitan G , et al. A randomized, double-blind, placebo-controlled, dose-ranging study of oral sildenafil citrate in treatment-naive children with pulmonary arterial hypertension. Circulation 2012; 125 (2) 324-334